Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion
Abstract
Donor lymphocyte infusions (DLIs) after allo-SCT displayed limited use in CLL and highly malignant non-Hodgkin's lymphoma (NHL). Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases. Six patients (three cases with p53-mutated CLL and three with high-grade NHL (HG-NHL)) refractory to standard therapy were treated with escalating doses of Bi20 (range 10-2000 microg) followed by DLI or SCT. Thereby, all CLL patients showed a prompt but transient clinical and hematological response. In one patient with HG-NHL, we observed a halt in progression for almost 4 months. Side effects (fever, chills and bone pain) were tolerable and appeared at antibody dose levels between 40 and 200 microg. The cytokine profile was characterized by transient increases of IL-6, IL-8 and IL-10. Neither human anti-mouse antibodies nor GVHD developed, allowing repeated treatment courses. In summary, the trifunctional antibody Bi20 induced prompt antitumor responses in extensively pretreated, p53-mutated alemtuzumab and rituximab refractory patients indicating its therapeutic potential.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a pilot study, all alemtuzumab- and rituximab-refractory patients with recurrent B cell malignancies, CLL or highly malignant lymphoma after allo-stem cell transplantation showed a prompt but transient clinical and hematological response to Bi20.
“In a pilot study, Bi20 was administered to six patients with recurrent B cell malignancies, CLL or highly malignant lymphoma after allo-stem cell transplantation.All alemtuzumab-and rituximab-refractory patients showed a prompt but transient clinical and hematological response, highlighting the high therapeutic potential of this triomab.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [32]
Cites
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210 · see citing works
Cheson, B. D., Bennett, J. M., Grever, M. R., Kay, N. E., Keating, M., O’Brien, S. J., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,815 · see citing works
Khouri, I. F., Keating, M. J., Körbling, M., Przepiorka, D., Anderlini, P. N., O'Brien, S., Giralt, S. A., Ippoliti, C. M., von Wolff, B., Gajewski, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2817 · Cited by 916 · see citing works
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal‐Céligny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 521 · see citing works
Burges, A., Wimberger, P., Kümper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., Pfisterer, J., Lichinitser, M., Makhson, A., Moiseyenko, V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2769 · Cited by 257 · see citing works
Self-citationRituximab therapy in malignant lymphoma
Coiffier, B. (2007) · Oncogene · doi:10.1038/sj.onc.1210376 · Cited by 231 · see citing works
Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets
Nikolic, B., Lee, S.-S., Bronson, R. T., Grusby, M. J., & Sykes, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7894 · Cited by 228 · see citing works
van Besien, K., Lima, M. J. G. D., Giralt, S., Df, M., Khouri, I., Rondón, G., Mehra, R. C., Andersson, B., Dyer, C., Cleary, K. R., et al. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700781 · Cited by 225 · see citing works
Porter, D., Levine, B. L., Bunin, N., Stadtmauer, E. A., Luger, S. M., Goldstein, S. C., Loren, A. W., Phillips, J., Nasta, S. D., Perl, A. E., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3373 · Cited by 219 · see citing works
Marks, D. I. (2002) · Blood · doi:10.1182/blood-2002-02-0506 · Cited by 216 · see citing works
Kiewe, P. M., Hasmüller, S., Kahlert, S., Heinrigs, M., Rack, B. K., Marmé, A., Korfel, A., Jäger, M., Lindhofer, H., Sommer, H. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2436 · Cited by 198 · see citing works
Self-citationZeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189 · see citing works
Self-citationThe Immunopathophysiology of Acute Graft‐Versus‐Host‐Disease
Ferrara, J. L. M., Cooke, K. R., Pan, L., & Krenger, W. (1996) · Stem Cells · doi:10.1002/stem.140473 · Cited by 182 · see citing works
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174 · see citing works
Self-citationRitgen, M., Stilgenbauer, S., Neuhoff, N. V., Humpe, A., Brüggemann, M., Pott, C., Raff, T., Kröber, A., Bunjes, D. W., Schlenk, R. F., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4321 · Cited by 170 · see citing works
Jazirehi, A. R., Vega, M. I., & Bonavida, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2184 · Cited by 167 · see citing works
Ghielmini, M. E. G., Rufibach, K., Salles, G., Leoncini, L., Falandry, C., Cogliatti, S., Fey, M. F., Martinelli, G., Stahel, R. A., Lohri, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi320 · Cited by 166 · see citing works
Bispecific antibodies in cancer therapy
Segal, D. M., Weiner, G. J., & Weiner, L. M. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00015-1 · Cited by 161 · see citing works
A revival of bispecific antibodies
Kufer, P., Lutterbüse, R., & Baeuerle, P. A. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.006 · Cited by 157 · see citing works
Bierman, P. J., Sweetenham, J. W., Loberiza, F. R., Taghipour, G., Lazarus, H. M., Rizzo, J. D., Schmitz, N., van Besien, K., Vose, J. M., Horowitz, M. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.054 · Cited by 146 · see citing works
Immunotherapy of malignant ascites with trifunctional antibodies
Heiss, M. M., Ströhlein, M. A., Jäger, M., Kimmig, R., Burges, A., Schoberth, A., Jauch, K., Schildberg, F., & Lindhofer, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21165 · Cited by 117 · see citing works
Self-citationSebastian, M., Passlick, B., Friccius-Quecke, H., Jäger, M., Lindhofer, H., Kanniess, F., Wiewrodt, R. G., Thiel, E., Buhl, R., & Schmittel, A. H. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0310-7 · Cited by 100 · see citing works
Self-citationStanglmaier, M., Faltin, M., Ruf, P., Bodenhausen, A., Schröder, P., & Lindhofer, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.23626 · Cited by 66 · see citing works
Self-citationGraft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology
Grigg, A., & Ritchie, D. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.05.008 · Cited by 54 · see citing works
The graft-versus-lymphoma effect: clinical review and future opportunities
Butcher, B., & Collins, R. H. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705008 · Cited by 52 · see citing works
Two new trifunctional antibodies for the therapy of human malignant melanoma
Ruf, P., Jäger, M., Ellwart, J., Wosch, S., Kusterer, E., & Lindhofer, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11630 · Cited by 52 · see citing works
Self-citationUnique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy
Friedberg, J. W. (2005) · Hematology · doi:10.1182/asheducation-2005.1.329 · Cited by 51 · see citing works
Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., & Slavin, S. (2005) · Blood · doi:10.1182/blood-2005-07-2738 · Cited by 28 · see citing works
Self-citationStemmler, H., Salat, C., Lindhofer, H., Menzel, H., Untch, M., Kahlert, S., Konecny, G., Sauer, H., Ledderose, G., Heinemann, V., et al. (2005) · PubMed · Cited by 18 · see citing works
Self-citationBrandl, M., Große‐Hovest, L., Holler, E., Kolb, H., & Jung, G. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00072-7 · Cited by 17 · see citing works
Self-citationKawano, I., Tsukada, J., Toda, Y., Ogawa, R., Higashi, T., Iwashige, A., Ota, T., Kubota, A., Mizobe, T., Morimoto, H., et al. (2004) · PubMed · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 585 · see citing works
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336 · see citing works
Redirecting T cells to hematological malignancies with bispecific antibodies
Velasquez, M. P., Bonifant, C. L., & Gottschalk, S. M. (2017) · Blood · doi:10.1182/blood-2017-06-741058 · Cited by 174 · see citing works
“FBTA05 has been used as monotherapy or followed by donor lymphocyte infusion (DLI) in the treatment of CLL, high grade NHL, ALL, post transplant lymphoproliferative disease (PTLD), in both adult and/or pediatric patients.(40,64,65) For example, 10 pediatric patients with relapsed/refractory B-cell malignancies receive…”
MethodA tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
Byrne, H., Conroy, P. J., Whisstock, J. C., & O’Kennedy, R. J. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.08.007 · Cited by 159 · see citing works
Deol, A., & Lum, L. G. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.004 · Cited by 139 · see citing works
Porter, D., Alyea, E. P., Antin, J. H., Lima, M. J. G. D., Estey, E. H., Falkenburg, J. H. F., Hardy, N. M., Kröger, N. M., Leis, J. F., Levine, J. E., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.08.001 · Cited by 136 · see citing works
“Buhmann and colleagues tested Bi20 in combination with DLI or stem cell-mobilized donor peripheral blood mononuclear cells (mobilized DLI) in previously allotransplanted patients [237].”
BackgroundDonor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
Roddie, C., & Peggs, K. S. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.554811 · Cited by 110 · see citing works
“Transient clinical responses were observed, but disease recurrence was identified soon after cessation of therapy, despite further doses of DLI [94].”
BackgroundRelapse after Allogeneic Hematopoietic Cell Therapy
van den Brink, M. R. M., Porter, D. L., Giralt, S. A., Lu, S. X., Jenq, R. R., Hanash, A. M., & Bishop, M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.10.023 · Cited by 96 · see citing works
“Newer antibodies designed either to directly target tumor cells or to recruit T cells directly to sites of disease also hold promise for relapsed patients [33].”
BackgroundTumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.004 · Cited by 83 · see citing works
Bispecific antibody platforms for cancer immunotherapy
Lameris, R., de Bruin, R. C. G., Schneiders, F. L., Henegouwen, P. M. P. V. B. E., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.003 · Cited by 82 · see citing works
“FBTA05 followed by donor lymphocyte infuion or peripheral blood stem cell transplantation showed a rompt but transient response in several patients [19].”
BackgroundEmerging classes of armed antibody therapeutics against cancer
Hess, C., Venetz, D., & Neri, D. (2014) · MedChemComm · doi:10.1039/c3md00360d · Cited by 47 · see citing works
Wudhikarn, K., Brunstein, C. G., Bachanová, V., Burns, L. J., Cao, Q., & Weisdorf, D. J. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.02.009 · Cited by 42 · see citing works
“Available potential treatment approaches include RIS, chemotherapy, rituximab, DLI [9,10,28], second allogeneic HCT [29,30], interleukin-2 [31], or other novel agents [32,33], yet reported outcomes are disappointing.”
Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer
Kobold, S., Steffen, J., Chaloupka, M., Grassmann, S. A., Henkel, J., Castoldi, R., Zeng, Y., Chmielewski, M. M., Schmollinger, J. C., Schnurr, M. M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju364 · Cited by 42 · see citing works
“Previous clinical studies have used BiAb to recruit T cells to tumor cells in patients (10,24,25).”
ResultThe intriguing options of multispecific antibody formats for treatment of cancer.
Weidle, U. H., Tiefenthaler, G., Weiss, E. H., Georges, G. J., & Brinkmann, U. (2013) · PubMed · Cited by 40 · see citing works
Buhmann, R., Stanglmaier, M., Heß, J., Lindhofer, H., Peschel, C., & Kolb, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-160 · Cited by 34 · see citing works
“These, included 4 patients with refractory Chronic Lymphocytic Leukemia (CLL), 4 patients with refractory high-grade non-Hodgkin Lymphoma (HG-NHL) and 1 patient with refractory Acute Lymphocytic Leukemia (ALL) [16].”
BackgroundInfluentialSelf-citationSchuster, F. R., Stanglmaier, M., Woessmann, W., Winkler, B., Siepermann, M., Meisel, R., Schlegel, P. G., Hess, J., Lindhofer, H., Borkhardt, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13242 · Cited by 33 · see citing works
“In line with our previous observations (Buhmann et al, 2009) we did not observe additional side effects when Lymphomun was combined with DLI and post SCT.”
BackgroundMethodResultInfluentialSelf-citationAllogeneic Immunotherapy to Optimize the Graft-versus-Tumor Effect: Concepts and Controversies
Porter, D. (2011) · Hematology · doi:10.1182/asheducation-2011.1.292 · Cited by 32 · see citing works
Cancer Therapy with Trifunctional Antibodies: Linking Innate and Adaptive Immunity
Heß, J., Ruf, P., & Lindhofer, H. (2011) · Future Oncology · doi:10.2217/fon.11.138 · Cited by 30 · see citing works
“[49]”
BackgroundSelf-citationInvestigational Immunotherapeutics for B-Cell Malignancies
Quintás‐Cardama, A., Wierda, W. G., & O'Brien, S. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8254 · Cited by 27 · see citing works
“bone pain) were tolerable and appeared at doses between 40 and 200 g.(87) An ongoing phase I/II clinical trial conducted in Germany is”
BackgroundHematopoietic stem cell transplantation and cellular therapy
Kolb, H. (2017) · HLA · doi:10.1111/tan.13005 · Cited by 27 · see citing works
“However, antibodies engaging effector cells are still to be studied in the allogeneic situation.(133) Other problems are related to antigen presentation: myeloma may require dendritic cell vaccines for recognition and low dose lenalidomide may be helpful for sustained remissions.”
BackgroundSelf-citationAllogeneic transplantation as anticancer immunotherapy
Parmar, S., & Ritchie, D. S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.010 · Cited by 24 · see citing works
de Jonge, A. V., Mutis, T., Roemer, M. G. M., Scheijen, B., & Chamuleau, M. E. D. (2020) · Cancers · doi:10.3390/cancers12103052 · Cited by 23 · see citing works
Multi-Specific Antibodies for Cancer Immunotherapy
Jachimowicz, R. D., Borchmann, S., & Rothe, A. (2014) · BioDrugs · doi:10.1007/s40259-014-0091-4 · Cited by 19 · see citing works
“Additionally, the trifunctional antibody design also provides a hybrid Fc region for interaction with Fc receptors [50].”
BackgroundNew antibody drug treatments for lymphoma
Mayes, S., Brown, N., & Illidge, T. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.560569 · Cited by 19 · see citing works
“The majority of data thus far for Bi20 relates to CLL, where it has been shown to have efficacy in killing CLL-derived B-cells [103], and in a Phase I trial where a patient with high-grade NHL had stable disease for 4 months [104].”
BackgroundDeppisch, N., Ruf, P., Eißler, N., Neff, F., Buhmann, R., Lindhofer, H., & Mocikat, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0156 · Cited by 18 · see citing works
“However, as trAbs are typically used in extremely low amounts, such effects have not been observed in clinical trials so far (8, 18, 19).”
BackgroundSelf-citationTrifunctional Triomab® Antibodies for Cancer Therapy
Lindhofer, H., Heß, J., & Ruf, P. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_16 · Cited by 12 · see citing works
Self-citationStröhlein, M. A., & Heiss, M. M. (2012) · Der Onkologe · doi:10.1007/s00761-012-2287-x · Cited by 10 · see citing works
Reddy, N. M., Greer, J. P., Goodman, S. A., Engelhardt, B. G., Oluwole, O. O., Jagasia, M., & Savani, B. N. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.10 · Cited by 8 · see citing works
Kieslich, A., Ruf, P., Lindhofer, H., Buhmann, R., Eggert, A., & Hundsdoerfer, P. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272687 · Cited by 8 · see citing works
Self-citationAdvances in therapies for non-Hodgkin lymphoma in children
Kobos, R., & Terry, W. W. (2015) · Hematology · doi:10.1182/asheducation-2015.1.522 · Cited by 7 · see citing works
Stem cell transplants for patients with relapsed/refractory leukaemia
Kolb, H., Simões, B. P., & Schmid, C. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283309647 · Cited by 7 · see citing works
Self-citationImmunotargeting and therapy of cancer by advanced multivalence antibody scaffolds
Kafil, V., Saei, A. A., Tohidkia, M. R., Barar, J., & Omidi, Y. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1772796 · Cited by 5 · see citing works
Effector Cell Recruitment by Bispecific Antibodies
Kellner, C., Peipp, M., & Valerius, T. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_13 · Cited by 4 · see citing works
Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia
von Stackelberg, A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8459-3_12 · Cited by 3 · see citing works
“4) [108].”
Boehrer, S., Schroeder, P., Mueller, T., Atz, J., & Chow, K. U. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328344887f · Cited by 3 · see citing works
T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases
Vdovin, A. S., Быкова, Н. А., & Efimov, G. A. (2017) · Molecular Biology · doi:10.1134/s0026893317060164 · Cited by 2 · see citing works
Use of PK / PD Knowledge in Guiding Bispecific Biologics Research and Development
Baumann, A., Prabhu, S., & Kanodia, J. (2015) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse562 · Cited by 3 · see citing works
Biology and Clinical Evaluation of T/NK Cell Engagers
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_17 · Cited by 1 · see citing works
The research and development of bispecific antibodies
Zhao, W. (2019) · AIP conference proceedings · doi:10.1063/1.5110811 · Cited by 1 · see citing works
Holtick, U., & von Bergwelt‐Baildon, M. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.24 · Cited by 1 · see citing works
Lindhofer, H., Stanglmaier, M., Buhmann, R., Jäger, M., Klunker, D., Ruf, P., & Heß, J. (2014) · doi:10.1002/9783527682423.ch51
Self-citationNew strategies for allogeneic hematopoietic stem cell transplantation with umbilical cord
Gertow, J. (2013) · Figshare
Bifunctional Antibodies: Preclinical and Clinical Applications
Shuptrine, C. W., & Weiner, L. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_10
“None of the six patients developed HAMA with Bi20 treatment and survival ranged from 38 to 486 days [ 20 ].”
BackgroundKolb, H., Atkinson, K., & Munker, R. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139519205.022
Self-citationPassive immunotherapy by T cell–engaging bispecific antibodies
Baeuerle, P. A., & Rattel, B. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848303.018
Hämatopoetische Stammzelltransplantation: seit Jahrzehnten etablierte Zelltherapie
Kolb, H., & Fehse, B. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_11
Self-citationSpenderlymphozytentransfusion nach allogener Stammzelltransplantation
Schmid, C., & Kolb, H. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01948-8
Self-citationClinical Development of Antibody-Fusion Proteins for Cancer Therapy
Alderson, K. L., Erbe, A. K., Boyden, M., & Sondel, P. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_11
“treated six B cell lymphoma patients that were refractory to standard therapy with an anti-CD3 X anti-CD20 TriomAb, Bi20, and followed Bi20 infusion with donor lymphocyte infusion (DLI) or hematopoietic stem cell transplant (HSCT) [ 8 ].”
Method
- Authors
- Buhmann, R., Simoes, B., Stanglmaier, M., Yang, T., Faltin, M., Bund, D., Lindhofer, H., & Kolb, H.-J.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Helmholtz Munich (DE)
- Corresponding author
- Buhmann, R
- ORCID
- Yang, T
- Venue
- Bone Marrow Transplantation
- Published
- 2008-10-13
- Volume
- 43
- Issue
- 5
- Pages
- 383-397
- ISSN
- 0268-3369 (ISSN-L)
- 1476-5365
- OpenAlex
- W2025130837
- Cited by
- 48
- References
- 32
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 1 · 2017: 4 · 2015: 4 · 2014: 8 · 2013: 7 · 2012: 2
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Bone Marrow Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leuka
- Deutscher Akademischer Austauschdienst
- Topics
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- donor lymphocyte infusion, allogeneic stem cell transplantation, chronic lymphocytic leukemia, high-grade non-Hodgkin's lymphoma, graft-versus-leukemia effect, cytokine profile, rituximab-refractory disease
- MeSH terms
- Adult, Female, Graft vs Host Disease, Humans, Male, Middle Aged, Pilot Projects, Recurrence, Tissue Donors, Transplantation, Homologous, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Hematopoietic Stem Cell Transplantation, Adoptive Transfer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
